Osteologix Inc. Announces Plans To File For European Marketing Authorization For Proprietary Osteoporosis Drug

Osteologix Inc. (OLGX.OB) announced that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix’ first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis…